Compare Quest Diagnostics Inc (DGX) vs 3M Company (MMM) Price & Performance

Quest Diagnostics (DGX) trades at $230.81, up 1.68% today, with a bullish earnings trend after beating EPS estimates for three consecutive quarters. The stock shows a mixed technical picture with a bearish overall signal but trades near key support at $228. Revenue growth accelerated to $11.04B in 2025, and the company maintains solid profitability with a 9.19% net income margin. Recent news highlights growth in consumer testing and a partnership with Apple Health, though Medicare reimbursement cuts pose a headwind.

The outlook is cautiously optimistic, supported by strong fundamentals and a consensus price target of $250 offering 8% upside. Key opportunities include demand for advanced diagnostics and AI adoption, while risks center on regulatory pressure and rising debt levels. Analyst sentiment is mixed with a slight hold bias, reflecting balanced growth prospects against near-term challenges.

3M (MMM) trades at $163.57, up 0.89% on the day, with a mixed technical picture showing bearish moving averages but neutral oscillators. The company reported strong Q2 2026 earnings, beating estimates with $2.40 EPS versus $2.25 expected, and raised full-year guidance. Revenue for 2025 was $24.95 billion with a net income margin of 11.9%, though profitability has moderated from prior years. Analysts maintain a consensus price target of $191.00, implying significant upside, with 48% recommending Buy.

The outlook for 3M is cautiously optimistic, driven by operational improvements and growth in industrial and electronics segments, but risks include high debt levels, weak consumer demand, and ongoing litigation costs. The stock's valuation at a P/E of 29.06 appears elevated relative to historical norms, requiring sustained earnings growth to justify further gains.